Leap Therapeutics Inc (NASDAQ:LPTX) Given $9.00 Average Target Price by Analysts
Leap Therapeutics Inc (NASDAQ:LPTX) has received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating. Leap Therapeutics’ rating score has improved by 24.8% in the last three months as a result of various analysts’ upgrades and downgrades.
Brokerages have set a twelve-month consensus price objective of $9.00 for the company and are expecting that the company will post ($0.40) earnings per share for the current quarter, according to Zacks. Zacks has also given Leap Therapeutics an industry rank of 58 out of 256 based on the ratings given to related companies.
Separately, Zacks Investment Research cut H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday.
Leap Therapeutics (NASDAQ:LPTX) last released its earnings results on Wednesday, May 15th. The company reported ($0.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.06). As a group, sell-side analysts predict that Leap Therapeutics will post -1.62 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Leap Therapeutics stock. Deutsche Bank AG grew its holdings in Leap Therapeutics Inc (NASDAQ:LPTX) by 45.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,338 shares of the company’s stock after purchasing an additional 39,000 shares during the period. Deutsche Bank AG owned about 0.58% of Leap Therapeutics worth $248,000 as of its most recent SEC filing. Institutional investors own 9.17% of the company’s stock.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Featured Article: Moving Average (MA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.